Abstract Ruthenium complexes offer potential reduced toxicity compared to current platinum anticancer drugs. 1, 2, 3, 4-tetrahydrisoquinoline amino alcohol ligands were synthesised, characterised and coordinated to an organometallic Ru (II) centre. These complexes were evaluated for activity against the cancer cell lines MCF-7, A549 and MDA-MB-231 as well as for toxicity in the normal cell line MDBK. They were observed to be moderately active ...